We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.
- Authors
Gladieff, L; Ferrero, A; De Rauglaudre, G; Brown, C; Vasey, P; Reinthaller, A; Pujade-Lauraine, E; Reed, N; Lorusso, D; Siena, S; Helland, H; Elit, L; Mahner, S
- Abstract
To perform a subset analysis of patients with partially platinum-sensitive recurrent ovarian cancer (ROC) who received either CD [carboplatin-pegylated liposomal doxorubicin (PLD)] or CP (carboplatin-paclitaxel) in the CALYPSO trial.
- Publication
Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Vol 23, Issue 5, p1185
- ISSN
1569-8041
- Publication type
Journal Article
- DOI
10.1093/annonc/mdr441